Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Combining atezolizumab to neoadjuvant chemotherapy does not improve pathologic complete response rates for TNBC patients

Share :

SABCS 2019
Published: 18 Dec 2019
Views: 832
Rating:
Save
Dr Luca Gianni - San Raffaele Hospital, Milan, Italy

Dr Luca Gianni gives a press conference at the 2019 San Antonio Breast Cancer Symposium about the combination of atezolizumab with neoadjuvant chemotherapy for the treatment of triple-negative breast cancer (TNBC).

Watch our interview with Dr Luca Gianni here.

Read more about the study here. 

Related Videos

EAU 2024: Bladder cancer latest
Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea...
EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )
9 Apr 2024
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )
25 Mar 2024
OncoAlert Round Up for August 25th - 31st, 2023
Dr Gil Morgan - Executive Director, OncoAlert
OncoAlert Round Up for August 25th - 31st, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )
4 Sep 2023
OncoAlert round up July 28th to August 3rd, 2023
Dr Gil Morgan - Executive Director, OncoAlert
OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )
4 Aug 2023
Management of HER2 positive metastatic breast cancer treatment algorithm
Prof Sandra Swain - Georgetown University Medical Center, Washington DC, USA
Management of HER2 positive metastatic breast cancer treatment algorithm ( Prof Sandra Swain - Georgetown University Medical Center, Washington DC, USA )
31 Jan 2023
Post neoadjuvant management in BRCA mutant breast cancer patients
Prof Banu Arun - MD Anderson Cancer Center, Houston, USA
Post neoadjuvant management in BRCA mutant breast cancer patients ( Prof Banu Arun - MD Anderson Cancer Center, Houston, USA )
31 Jan 2023
Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced...
Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA
Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )
21 Sep 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation